DAWN Q2 2023 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$92,000

Operating Income

-$49M

Net Income

-$46M

EPS (Diluted)

$-0.61

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$43M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$451M

Total Liabilities

$25M

Stockholders' Equity

$426M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$92,000	-$133,000	+30.8%
Operating Income	-$49M	-$37M	-34.1%
Net Income	-$46M	-$37M	-25.5%